NeuroNEXT

The results of the NN102 SPRINT-MS have been posted online at the New England Journal of Medicine.  

The National Institute of Neurological Disorders and Stroke announced the renewal of the NeuroNEXT Network for an additional five years of funding. 

The University of Iowa highlighted NeuroNEXT achievements in two campus publications: Iowa Now provides an overview of the ways the Network is accelerating the clinical trials process, and The Daily Iowan focuses on the ways NeuroNEXT is bringing together clinical sites and coordinating centers to advance neurological trials. In addition, the College of Public Health at the University of…

The Clinical Trials Methodology Course (CTMC) has begun their 2018 Webinar Series. These webinars are open to all. The course focues on the desing of early stage clinical trials for investigators focused on neurological illness and injury. The full scheduled may be viewed online: https://siren.network/training/ctmc/ctmc-webinars.  The NINDS Clinical Trials Methodology Course is supported by the NIH-NINDS:…

Neuro Central Podcast NC Talks featured an interview with Dr. Robert Fox, PPI of the NN102 SPRINT-MS study. Dr. Fox discussed trial results with the podcasters at the American Academy of Neurlogy’s 70th Annual Meeting in Los Angeles, CA. 

The American Academy of Neurology (AAN) Annual Meeting will begin April 21 in Los Angeles, CA. The following NeuroNEXT events and presentations will take place: Please visit the AAN Annual Meeting site for more information on the plenary sessions or emerging science program.  Related Projects:  NN102 SPRINT-MS NN103 Beat MG

Network successes and the five-year renewal application were presented at the 2018 Annual Meeting of the American Society for Experimental Neurotherapeutics poster session. The poster, presented March 9 at the meeting’s poster presentation and reception, concluded that NeuroNEXT has met all of its initial goals within the first 7-year funding period; that Network sites hae demonstrated their…

In the same issue where the NN101 SMA primary results were published, the Annals of Neurology also published an accompanying editorial with high praise for the Network. The authors noted that “NeuroNEXT is clearly trying to change the landscape of clinical trials in neurology, helping to empower the academic investigator to pursue research efforts that would otherwise be impossible.”

Results of the NN104 study were covered  in the San Diego Union-Tribune. The article details the development of 3K3A-APC, the study drug, originally developed by The Scripps Research Institute in La Jolla, CA.

Final results from the NN104 RHAPSODY trial, which were presented at the International Stroke Conference (ISC) 2018 as a closing event, were subsequently featured in ISC’s Science News as Featured Science and on the American Stroke Association blog “Blogging Stroke.”